Alliance Pharma Four-Month Sales Rose on Year, But Sees Full-Year FX Hit
25 Mai 2023 - 10:18AM
Dow Jones News
By Adria Calatayud
Alliance Pharma said Thursday that sales for the first four
months of 2023 were higher than in the year-earlier period, but
warned that adjusted pretax profit for the full year will be
marginally lower than expected due foreign-exchange moves and
rising interest rates.
The U.K. consumer-healthcare company didn't provide specific
figures, but said demand for its Kelo-Cote product in China has
continued to recover as expected.
"Whilst the business is on track to meet the board's full year
expectations for revenue and adjusted [earnings before interest,
taxes, depreciation and amortization], adverse currency movements,
particularly the recent strengthening of U.K. sterling against the
U.S. dollar, and the rising interest rate environment, mean that
full year adjusted profit before tax is expected to be marginally
below current expectations," Chair David Cook said.
Write to Adria Calatayud at adria.calatayud@dowjones.com to
Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
May 25, 2023 04:03 ET (08:03 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Alliance Pharma (LSE:APH)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Alliance Pharma (LSE:APH)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024